0
Business
Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
April 15, 2026
Scroll
Posted 2 hours ago by
Portal Innovations CEO John Flavin provides a look into the 2026 biotech MA pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to 300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)
Bloomberg
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.